INTRODUCTION
Treatment strategies in rheumatoid arthritis (RA) have rapidly advanced over the past decade to include earlier identification and initiation of treatment in clinically classifiable RA. Although this approach has led to improved outcomes related to joint damage and disability, the number of RA patients that achieve sustained drug-free remission remains low [1] [2] [3] . Therefore, in order to 'cure' RA and prevent joint damage, interventions prior to the onset of joint inflammation are very likely to be necessary. Unfortunately, a major limitation to developing effective preventive strategies for RA has been a lack of ability to detect and classify individuals that are at high risk for RA, as well as limitations in our knowledge of the mechanisms of disease development, including identification of when and at what anatomic site RA begins. However, in recent years, there has been a greatly increased understanding of the mechanisms of early RA development. Herein, we will review these data, with a focus on when and where RA may begin, as well as identify areas of additional study that are required in this area.
PRECLINICAL RHEUMATOID ARTHRITIS
It is well established that RA-related autoantibodies can be elevated in the serum on average 3-5 years (and in some cases >10 years) prior to the onset of joint inflammation in RA. This finding is supported by data from multiple prospective and retrospective studies evaluating samples that were collected and stored prior to the onset of clinically apparent RA. These RA-related autoantibodies are listed in Table 1 and are highly specific for future disease [4] [5] [6] [7] [8] [9] 10 Studies of autoantibodies in the preclinical period of RA have provided insights into the evolution of autoimmunity in RA. For example, autoantibody levels rise during the preclinical period as time to RA diagnosis decreases [6, 7] . Additionally, there are changes in autoantibody characteristics during preclinical RA, including isotype, avidity, glycosylation and epitope spreading. Nielsen et al. [11] recently demonstrated that a doubling of serum rheumatoid factor-IgM level was associated with more than three-fold increased risk of developing RA, and Ercan et al. [16] demonstrated that as the time to diagnosis approaches in preclinical RA, there is increasing aberrant glycosylation that promotes complement activation and Fc receptor engagement. Suwannalai et al. [17] demonstrated that the avidity of antibodies to citrullinated protein antigens (ACPAs) increases over time in preclinical RA, although this process appears to halt once clinically apparent disease is present, a finding that suggests there is a threshold that must be reached prior to the onset of synovitis. Furthermore, using a bead-based array to test antibodies to multiple individual citrullinated proteins/peptides, Sokolove et al. [13 && ] demonstrated that there is epitope spreading in the preclinical RA period. Another study by Brink et al.
[14 && ] evaluated individual ACPAs in preclinical RA samples, and they demonstrated that an increased number of positive ACPAs had a higher specificity for future RA. Similarly to what was seen in the Sokolove study, Brink et al. also found that systemic autoimmunity in RA was initially restricted to a small number of ACPAs that expanded as time to RA diagnosis approached. Of interest, the ACPAs detected earliest in the preclinical period were found to be the least stable in longitudinal samples. Other studies [18, 19] have similarly demonstrated that autoantibody levels and reactivity may fluctuate over time, including during the preclinical RA period.
In addition to autoantibodies, multiple studies [13 && ,20-23] have identified abnormalities of biomarkers that are reflective of systemic inflammation during the preclinical RA period, including circulating cytokines, chemokines and variably C-reactive protein. A recent study by Hughes-Austin et al. [20] found an elevated cytokine score that encompasses multiple inflammatory cytokines was associated with elevations of serum RA-related autoantibodies in unaffected first-degree relatives (FDRs) of probands with RA. Furthermore, these inflammatory biomarker dynamics may predict the likelihood and timing of future RA. For example, Deane et al. [22] found in a study using preclinical US Military samples that an increasing number of elevated cytokines/chemokines was associated with a shorter
KEY POINTS
Systemic inflammation and autoimmunity are detectable years prior to the onset of detectable joint inflammation in RA suggesting RA is initially generated outside of the joints.
Several mucosal surfaces have the potential to be a site for initial immune dysregulation and autoantibody generation in RA.
Additional investigations into the mechanisms by which inflammation and autoimmunity develop at a mucosal site are needed in order to understand how RA begins.
An improved understanding of the earliest steps in the development of RA can lead to organ-targeted mechanism-specific strategies for RA prevention. ] found that an increased number of ACPAs along with elevated cytokines was 58% sensitive and 87% specific for a diagnosis of RA within 2 years.
However, the temporal relationship between the elevations of autoantibodies and abnormalities of systemic inflammation during the preclinical RA period has been difficult to clarify. The Sokolove study [13 && ] found that increasing number of ACPAs preceded the timing of increasing levels of systemic inflammatory cytokines. However, in a crosssectional study, El-Gabalawy et al. [24] found cytokine/chemokine elevations in Native American FDRs in the absence of autoantibodies.
Overall these findings suggest that there is a period of preclinical RA development during which there is an initial restricted immune response that expands over time in regard to magnitude and breadth of responses. In particular, for ACPArelated autoimmunity, targets of autoimmunity may change over time, with some early antigens perhaps reflecting initial autoimmunity, and later antigens representing epitope spreading, and potentially reactivity to more pathogenic targets. Although it is not yet clear if certain inflammatory pathways precede the development of autoimmunity, it is reasonable that there is initially some degree of local or systemic inflammation that is associated with the early development of autoimmunity in RA, and then both inflammatory and autoimmune processes expand over time until clinically apparent arthritis develops.
Where does rheumatoid arthritis begin?
Based on the data discussed above, systemic inflammation and autoimmunity precede the onset of clinically classifiable RA; however, it is not clear where these processes initially develop in RA. Although plasma cells in the synovium have been shown to generate autoantibodies in patients with established RA [25, 26] , studies evaluating the joint during the preclinical period have generally found that the synovium does not appear to be affected in this early stage of RA development. Specifically, van de Sande et al. [27] found no histologic or MRI evidence of synovial inflammation in the knee in individuals with serum RA-related autoantibodies without clinically evident synovitis. In some contrast, subclinical joint inflammation was reported using ultrasound, MRI and PET imaging in a small number of individuals with serum ACPAs, joint symptoms of 'arthralgias', and no clinically evident synovitis [28] [29] [30] . However, the specificity of these imaging findings is uncertain, and the majority of the ACPA positive individuals that were evaluated in these studies had no clinical or imaging evidence of synovitis, including several that later developed synovitis classifiable as RA. Overall, these data suggest that the initial inflammation and autoimmunity in RA begins outside of the joints.
If RA-related autoimmunity develops outside of the joints, where is that site? Several lines of evidence support that RA-related autoimmunity may originate at a mucosal site (Table 2) [19, 27, 31, 32 & ,33,34 && , [35] [36] [37] , and an overview of this hypothesis is depicted in Fig. 1 . In particular, IgA is the predominant antibody of the mucosal immune system, and data demonstrate IgA-ACPAs are elevated and highly specific for RA in individuals with preclinical and early classifiable RA [38] [39] [40] . Furthermore, Barra et al. [40] found that 41% of serum ACPA positivity in unaffected FDRs of probands with RA was IgA. Additionally, as discussed below, findings related to specific mucosal sites including the oral cavity, the lungs and the gut suggest that environmental factors that may preferentially affect the mucosa appear to play an important role in the early pathogenesis of RA.
It is also of note that the cause of other rheumatic diseases supports the generation of autoimmunity associated with mucosal processes. For example, the cause of rheumatic fever is well established to result from a dysregulated immune response to Streptococcus infection of the pharyngeal mucosa that results in autoimmune-mediated injury of other tissues, including the joints [41] . In addition, reactive arthritis is another systemic inflammatory arthritis that can be initiated by infection and inflammation at a mucosal site (i.e. the gastrointestinal or genitourinary mucosa) [42] .
The oral mucosa and rheumatoid arthritisrelated autoimmunity In recent years, the oral mucosa, specifically the gingiva and periodontal regions, has been studied as a potential site for the origins of RA. In classifiable RA, there are an increased prevalence and severity of periodontitis that has been associated with systemic RA-related autoantibodies [43] [44] [45] [46] , and in individuals without classified RA, severe periodontitis has also been associated with RA-related autoantibodies [47] . In addition, Porphyromonas gingivalis (P. ging), a microbe commonly involved in periodontitis, is uniquely found to express a peptidylarginine deiminase (PAD) enzyme capable of citrullinating human peptides/proteins [48, 49] . Furthermore, in individuals without classified RA, Mikuls et al. [31] identified an association between the elevations of antibodies to P. ging and serum RA-related autoantibodies, and inflamed gingival tissue has been shown to express increased levels of PAD and citrullinated proteins [50,32 & ]. Of interest, Harvey et al. [32 & ] also identified the presence of local anti-cyclic citrullinated peptide (anti-CCP) antibodies in gingival crevicular fluid associated with gingivitis. However, despite these intriguing associations, a recent study by Scher et al. [51 & ] found that P. ging was associated with the severity of periodontitis but not specifically associated with new-onset RA. Rather, they found that Prevotella and Leptotrichia were expanded in new-onset RA, and Anaeroglobus geminatus was associated with RA-related autoantibody positivity.
As such, going forward, longitudinal studies are needed that can simultaneously evaluate the relationship between oral pathogens, local gingival 
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Macrophage Lymph node T cell FIGURE 1. Hypothesis for the mucosal initiation of autoimmunity in rheumatoid arthritis (RA). These pictures represent a stepby-step overview of the hypothesis that an environmental factor interacting at a mucosal surface can result in a local immunemediated inflammatory reaction (Step 1). In some cases, and likely related to genetic factors, this inflammation triggers an autoimmune response that is initially localized (Step 2), but over time becomes systemic with circulating RA-related autoantibodies detected in the blood (Step 3). Finally, after a period of circulating preclinical RA-related autoimmunity, joint inflammation clinically classifiable as RA may develop (Step 4).
autoantibody generation, systemic RA-related autoimmunity, and joint inflammation in order to better understand the role of the oral mucosa in the cause of RA.
The lung and rheumatoid arthritis-related autoimmunity
Another mucosal surface that is a potential originating site of autoimmunity in RA is the lung. This possibility is supported by established data that demonstrate increased RA risk is associated with inhaled exposures such as cigarette smoke [52] [53] [54] , and a high prevalence of lung disease including airways inflammation has been identified in established RA [33, 77] . Furthermore, Demoruelle et al. [33] recently identified a higher prevalence of inflammatory airways disease by computed tomographic imaging in arthritis-free individuals (by joint examination and in a subset of individuals, by MRI) with serum RA-related autoantibodies compared with autoantibody-negative matched controls. Importantly, this finding was independent of prior or current cigarette smoking. Additionally, Fischer et al. [55] found 80% of anti-CCP positive individuals with chronic lung disease and no joint symptoms had imaging evidence of airways inflammation; furthermore, in a subset of these individuals that had a lung biopsy, 96% demonstrated histologic evidence of lung inflammation. Importantly, in these two studies, five individuals developed synovitis classifiable as RA during longitudinal follow up, and all five had the evidence of lung inflammation preceding the development of clinically apparent arthritis. Although these findings demonstrate that lung disease may precede articular disease in RA, it is not clear if that is because the lung is a site of initiation of RA-related autoimmunity, or an earlier target of the same autoimmune-mediated injury that affects the joints (the same argument can be made about oral inflammation and RA). However, recent findings from Willis et al. [34 && ] suggest that at least in some individuals, RA-related autoimmunity may originate in the lung. In this study, a subset of arthritis-free individuals had rheumatoid factor and/or anti-CCP antibodies present in their sputum that were not present in their serum, or that were present in higher levels in their sputum compared with their serum, suggesting that in this subset, these RA-related autoantibodies are generated in the lung.
As for potential mechanisms of mucosal generation of autoimmunity, in patients with chronic RA-related lung disease that underwent biopsy, an increased prevalence of inducible bronchus-associated lymphoid tissue (iBALT) was demonstrated in RA lung tissue compared with patients with other forms of lung disease [35] . Of interest, these areas of iBALT in RA patients included plasma cells generating RA-related autoantibodies. Thus, iBALT may represent a mechanism by which RA-related autoimmunity is generated in the lung. Similar areas of mucosal-associated lymphoid tissue (MALT) may serve as a site for the development of autoimmunity in other mucosal regions.
The gut and rheumatoid arthritis-related autoimmunity
To date, much of the data investigating the gastrointestinal mucosa in RA have focused on the gut microbiome. The gut microbiome is known to influence the development of the innate and adaptive immune system, and may therefore also play a role in the development of autoimmunity [56, 57] . In murine studies [58] [59] [60] , specific alterations of gut bacteria can enhance or attenuate susceptibility to experimentally induced arthritis. In humans, studies [36, 37] have identified differences in the gut microbiota, specifically differences in relative abundance of various microbes, in patients with classifiable RA compared with controls. However, these studies have been unable to distinguish whether differences in gut microbial communities are a cause of inflammation in RA, the result of an underlying inflammatory environment that selects for the survival of certain microbes, or whether the therapies used in RA are responsible for altering the gut microbial composition. Additional study of individuals prior to the onset of joint inflammation will be informative to understand the relationship between the gastrointestinal microbiome and the development of RA.
In summary, there is compelling evidence linking the mucosa of the oral cavity, lung and gut with the development of RA. However, other sites such as the nasopharyngeal, genitourinary and cervicovaginal mucosa have similar biologic features, including the formation of MALT. They are also exposed to a variety of environmental factors that could trigger inflammation, and as such, may serve as potential sites for geneticenvironmental immune reactions that could lead to RA. Although controversial, associations between serologic evidence of infection with organisms such as Proteus species that can cause urinary tract infections and RA suggest a potential role for genitourinary inflammation and RA development [61, 62] . In addition, cervicovaginal inflammation could help to explain the strong association between female sex and RA. Also, it may be that different mucosal sites are responsible for the generation of autoimmunity in different individuals that develop RA, and perhaps a key linkage between mucosal inflammation and RA is the development of systemic pathogenic autoimmunity to citrullinated antigens and rheumatoid factor. These issues will require further well designed human studies as well as relevant animal models of disease.
IMMUNOLOGIC MECHANISMS THAT MAY BE INVOLVED IN THE MUCOSAL INITIATION OF RHEUMATOID ARTHRITIS
Along with considering when and where RA begins, it is also important to consider what immune processes are involved in the loss of tolerance to citrullinated and other autoantigens, as well as how autoimmunity that may initially develop at an extra-articular site can move to the joint perhaps several years later, and result in synovitis. In particular, there are several potential immunologic mechanisms by which breaks in tolerance to self-antigens occur at mucosal surfaces. For example, toll-like receptor (TLR) signaling is an innate immune response to microorganisms and other factors that has also been implicated in autoimmune responses [63] . Specifically, TLR binding of endogenous nuclear material aberrantly released during apoptosis has been associated with the development of autoimmunity in systemic lupus erythematosus [64] , and similar mechanisms may be involved in RA as apoptosis is known to be associated with the generation of citrullinated endogenous proteins through the actions of PADs [65] . Furthermore, microbial factors present at mucosal surfaces may lead to molecular mimicry, or inflammation that in turn generates autoantibodies. For example, certain organisms such as P. ging may citrullinate human tissues [48] , or neutrophil migration to a mucosal site may lead to tissue citrullination because of the release of PADs [65] . In addition, neutrophil extracellular traps (NETs) containing citrullinated peptides that are released by activated neutrophils may externalize these citrullinated peptides, thereby resulting in the generation of ACPAs [66 && ]. Other mechanisms may include an altered balance between regulatory and autoreactive T cells. In addition, elevations of rheumatoid factor, even in the absence of articular RA, have been associated with mucosal inflammation such as in periodontal disease and non-RA lung disease (i.e. infection-related lung diseases such as cystic fibrosis and tuberculosis) [67] [68] [69] . In aggregate, these data suggest there may be a link between mucosal inflammation and the generation of rheumatoid factor as well as autoimmunity to citrullinated proteins/peptides.
Finally, there are additional immunologic mechanisms to consider that may be involved in the transition of autoimmunity from an initial extra-articular site to later involve the joints. Such possibilities include immune complex formation and deposition, shared antigenic targets between a site of initiation of RA-related autoimmunity and the joints, epitope spreading that leads to the generation of autoimmunity directed to joint proteins, and migration of activated T cells. Specifically, Zhao et al. [70] demonstrated circulating immune complexes containing citrullinated fibrinogen in individuals with classified RA as well as colocalization of fibrinogen, immunoglobulin and complement in RA joint tissue suggesting these circulating immune complexes can deposit in the synovium, resulting in complement-mediated synovitis. In addition, Ytterberg et al. [71] have identified a shared citrullinated vimentin protein in the lung and joint tissue of individuals with classifiable RA, and vaccination studies demonstrate that antigen-specific T-cell responses initiated at one mucosal surface can traffic to other organs [72] . These mechanisms will be important to study in order to gain a clear understanding of how autoimmunity may move from one site to another in RA, especially because blocking this transition at the right time in RA development may lead to disease prevention.
CONCLUSION
The data and concepts reviewed herein illustrate recent advances in the understanding of when and where RA begins; however, further study is needed to gain a deeper understanding of the mechanisms of RA development, especially in relationship to the site of initiation of RA. Of importance, although some studies of preclinical RA have been prospective, many of the studies providing information regarding immunologic and inflammatory processes in the preclinical period have been retrospective biobank/serum repository studies. As such, they have certain limitations including temporal irregularity of collection of samples and lack of detailed clinical data from the time of sampling (i.e. did the participant really have synovitis at the time of sample collection?). With these limitations, it is difficult to determine the exact timing of onset and evolution of RA-related autoimmunity. Furthermore, such studies cannot evaluate individuals in real time for biologic processes, such as mucosal inflammation, that may influence autoimmunity.
Therefore, a crucial part of advancing this knowledge will be prospective natural history studies that can evaluate individuals at risk for RA in real time and allow mechanistic studies of disease development. Several such natural history studies [40, [73] [74] [75] [76] are underway and will likely provide valuable contributions to the understanding of preclinical RA. These include studies such as the Studies of the Etiology of RA (SERA) project, the North American Natives (NAN) study and several research groups that have begun to evaluate FDRs in Korea, Sweden and Canada. In addition, preclinical RA research must advance to investigate specific immunologic mechanisms by which RA is generated at mucosal surface, or other potential sites, and results in joint disease. Although some of these studies can be performed using biologic samples obtained from human individuals, it may be difficult to obtain adequate materials in a well tolerated manner. Consequently, informative animal models will also be crucial in understanding specific pathways of disease development. However, driving these studies should be the hope that improved understanding of the specific mechanisms of RA development may ultimately lead to prevention strategies for this disease.
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